Trial Profile
A Multicenter Phase II Study of Treatment With Hu3S193 in Women With Advanced Breast Cancer That Progressed After Hormonal Therapy
Status:
Suspended
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Monoclonal antibody 3S193 (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 26 Nov 2018 Planned End Date changed from 1 Oct 2018 to 1 Nov 2018.
- 17 Apr 2018 Planned End Date changed from 1 Oct 2017 to 1 Oct 2018.
- 09 Dec 2017 Results (n=49) presented at the 40th Annual San Antonio Breast Cancer Symposium